Relapsed or Refractory Hematological Malignancies
3 clinical trials · Condition
◉ Watch Relapsed or Refractory Hematological Malignancies
| Record | Firm | Date |
|---|---|---|
| A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies (NCT04011293) | Shandong University | 2019-07-01 |
| Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies (NCT00904787) | CASI pharmaceuticals, Inc. | 2009-04-01 |
Track Relapsed or Refractory Hematological Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.